1. Home
  2. LTRX vs IMUX Comparison

LTRX vs IMUX Comparison

Compare LTRX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantronix Inc.

LTRX

Lantronix Inc.

HOLD

Current Price

$5.86

Market Cap

247.5M

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$10.59

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRX
IMUX
Founded
1989
2016
Country
United States
United States
Employees
N/A
66
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.5M
155.8M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
LTRX
IMUX
Price
$5.86
$10.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$6.50
$36.00
AVG Volume (30 Days)
1.2M
275.8K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
65.52
38.00
EPS
N/A
N/A
Revenue
$120,899,000.00
N/A
Revenue This Year
$1.12
N/A
Revenue Next Year
$15.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.37
$0.51
52 Week High
$8.75
$17.43

Technical Indicators

Market Signals
Indicator
LTRX
IMUX
Relative Strength Index (RSI) 57.67 30.68
Support Level $5.08 $0.78
Resistance Level $6.09 $15.82
Average True Range (ATR) 0.27 0.98
MACD 0.07 -0.37
Stochastic Oscillator 77.16 9.23

Price Performance

Historical Comparison
LTRX
IMUX

About LTRX Lantronix Inc.

Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The company operates in a single operating segment: the development, marketing, and sale of industrial and enterprise IoT products and services. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the U.S, Canada and the Rest of the World. The U.S contribute the vast majority of total revenue.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: